Home Cart Sign in  
Chemical Structure| 63223-86-9 Chemical Structure| 63223-86-9

Structure of Ginsenoside Rh1
CAS No.: 63223-86-9

Chemical Structure| 63223-86-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ginsenoside Rh1 (Prosapogenin A2) inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β.

Synonyms: Prosapogenin A2; Sanchinoside Rh1; CS-3834

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ginsenoside Rh1

CAS No. :63223-86-9
Formula : C36H62O9
M.W : 638.87
SMILES Code : C[C@]12[C@@]3(C)[C@@](C[C@@H](O)[C@]1([H])[C@]([C@@](C)(O)CC/C=C(C)/C)([H])CC2)([H])[C@](CC[C@H](O)C4(C)C)(C)[C@@]4([H])[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C3
Synonyms :
Prosapogenin A2; Sanchinoside Rh1; CS-3834
MDL No. :MFCD09951797

Safety of Ginsenoside Rh1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Ginsenoside Rh1

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human vascular endothelial cells 25 mg/mL and 50 mg/mL 24 hours Ginsenoside Rh1 significantly increased the proliferation and decreased the apoptosis of ox-LDL-treated VECs in a dose-dependent manner. Moreover, ginsenoside Rh1 relieved oxidative stress in ox-LDL-treated VECs by activating the Nrf2/HO-1 signaling pathway. J Cardiovasc Pharmacol. 2022 Mar 1;79(3):335-341
MH-S cells 78.26 μM 3 hours Evaluate the inhibitory effect of Ginsenoside Rh1 on LPS-induced inflammatory response Front Pharmacol. 2021 Oct 27;12:709702
Rat aortic smooth muscle cells (RASMCs) 25 and 50 µM 24 hours Rh1 dose-dependently suppressed Ang II-induced cell proliferation and migration, concomitantly reducing protein levels of MMP2, MMP9, PCNA, and cyclin D1. Antioxidants (Basel). 2022 Mar 27;11(4):643
MDA-MB-231 cells 25, 50, 100 μM 12 hours To investigate the inhibitory effects of Rh1 on migration and invasion of MDA-MB-231 cells. Rh1 treatment significantly inhibited BC metastasis by inhibiting the both protein and mRNA levels of MMP2, MMP9, and VEGF-A. Int J Mol Sci. 2021 Sep 28;22(19):10458
MDA-MB-231 cells 25, 50, 100 μM 24 hours To evaluate the cytotoxic effect of Rh1 on MDA-MB-231 cell viability. Rh1 significantly inhibited the viability of MDA-MB-231 cells and increased the number of apoptotic cells. Int J Mol Sci. 2021 Sep 28;22(19):10458
Peritoneal macrophages 25 μg/mL 20 minutes To assess LPS binding to TLR4, results showed that the combination of Rg2 and Rh1 significantly inhibited LPS binding to TLR4. Int J Mol Sci. 2020 Sep 11;21(18):6656
RAW264.7 cells 0 to 50 μg/mL 24 hours To evaluate cell viability and inflammatory mediator production, results showed that Rh1 and the combination of Rg2 and Rh1 significantly reduced LPS-induced inflammatory mediator production and iNOS expression. Int J Mol Sci. 2020 Sep 11;21(18):6656
MCF-7 cells 10, 25, 50, 100 µM 10 days To evaluate the effect of Rh1 on colony formation in MCF-7 cells, the results showed that Rh1 significantly inhibited colony formation. Cancers (Basel). 2021 Apr 15;13(8):1892
BT474 cells 25, 50, 100, 150 µM 72 hours To evaluate the effect of Rh1 on the viability of BT474 cells, the results showed that Rh1 had a weak inhibitory effect on BT474 cells with an IC50 value greater than 150 µM. Cancers (Basel). 2021 Apr 15;13(8):1892
HCC1428 cells 25, 50, 100, 150 µM 72 hours To evaluate the effect of Rh1 on the viability of HCC1428 cells, the results showed that Rh1 significantly inhibited cell viability with an IC50 value of 147.4 µM. Cancers (Basel). 2021 Apr 15;13(8):1892
murine macrophage cell line (RAW 264.7) 100 μM 48 hours Evaluate the cytotoxicity of PEG-Rh1 on RAW 264.7 cells, results showed no significant cytotoxicity Molecules. 2019 Nov 29;24(23):4367
human non-small cell lung cancer cell line (A549) 100 μM 48 hours Evaluate the cytotoxicity of PEG-Rh1 on A549 cells, results showed PEG-Rh1 had higher cytotoxicity than Rh1 Molecules. 2019 Nov 29;24(23):4367
RAW 264.7 Murine macrophage cells 100 µg/mL 24 hours To evaluate the cytotoxic effect of G-Rh1 on RAW 264.7 cells, results showed low toxicity at 100 µg/mL Molecules. 2022 Nov 28;27(23):8311
A549 lung cancer cells 100 µg/mL 24 hours To evaluate the cytotoxic effect of G-Rh1 on A549 cells, results showed significant inhibition of cell proliferation at 100 µg/mL Molecules. 2022 Nov 28;27(23):8311

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
ICR mice LPS-induced acute liver and kidney injury model Intraperitoneal injection 20 mg/kg Single injection, lasting 6 or 24 hours To evaluate the protective effects against LPS-induced acute liver and kidney injury, results showed that the combination of Rg2 and Rh1 significantly alleviated histopathological damage and inflammatory responses. Int J Mol Sci. 2020 Sep 11;21(18):6656
Nude mice MCF-7 cell xenograft model Intraperitoneal injection 2 and 5 mg/kg Every three days for 16 days To evaluate the antitumor effect of Rh1 in vivo, the results showed that Rh1 significantly reduced tumor volume and weight, increased ROS production and the expression of LC3B and cleaved caspase-3, and decreased Akt phosphorylation. Cancers (Basel). 2021 Apr 15;13(8):1892
SD rats High-fat diet-induced NAFLD model Intraperitoneal injection 3 mg/kg/day Once daily for 1 week Evaluate the therapeutic effects of Rh1 on HFD-induced NAFLD. Results showed that Rh1 significantly improved liver function, lipid metabolism, and insulin resistance, and reduced liver fibrosis. Sci Rep. 2017 Jan 20;7:41144
Sprague-Dawley rats COPD rat model Oral 5.5 mg/kg/d Once daily for 8 weeks Evaluate the therapeutic effect of Ginsenoside Rh1 on COPD rats Front Pharmacol. 2021 Oct 27;12:709702

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.57mL

0.31mL

0.16mL

7.83mL

1.57mL

0.78mL

15.65mL

3.13mL

1.57mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories